LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Kodu・Aktsiate loetelu・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Suletud

SektorTervishoid

98.73 2.66

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

94.62

Max

99.13

Põhinäitajad
By Trading Economics
Sissetulek	-6.3M -53M
Müük	2.8M 51M
Aktsiakasum	-0.82
Kasumimarginaal	-103.131
Töötajad	283
EBITDA	-7.6M -48M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+49.37% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 6.4B
Eelmine avamishind	96.07
Eelmine sulgemishind	98.73

Uudiste sentiment

By Acuity

64%

36%

126 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

60 / 65.58 Toetus ja vastupanu

Rhythm Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. veebr 2026, 23:07 UTC

Tulu

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 23:01 UTC

Tulu

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:59 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24. veebr 2026, 22:42 UTC

Tulu

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24. veebr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24. veebr 2026, 23:46 UTC

Market Talk

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24. veebr 2026, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24. veebr 2026, 23:30 UTC

Market Talk

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24. veebr 2026, 23:20 UTC

Market Talk

Global Equities Roundup: Market Talk

24. veebr 2026, 23:16 UTC

Tulu

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24. veebr 2026, 23:13 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24. veebr 2026, 23:12 UTC

Tulu

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24. veebr 2026, 23:10 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24. veebr 2026, 23:08 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24. veebr 2026, 23:07 UTC

Tulu

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24. veebr 2026, 22:52 UTC

Tulu

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24. veebr 2026, 22:46 UTC

Tulu

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24. veebr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Warner Receives New Bid From Paramount -- 3rd Update

24. veebr 2026, 22:29 UTC

Tulu

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24. veebr 2026, 22:28 UTC

Tulu

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24. veebr 2026, 22:27 UTC

Tulu

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24. veebr 2026, 22:25 UTC

Tulu

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24. veebr 2026, 22:24 UTC

Tulu

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24. veebr 2026, 22:23 UTC

Tulu

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24. veebr 2026, 22:22 UTC

Tulu

Woolworths Interim Dividend 45 Australian Cents/Share

24. veebr 2026, 22:22 UTC

Tulu

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24. veebr 2026, 22:21 UTC

Tulu

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Võrdlus sarnastega

Hinnamuutus

Rhythm Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

49.37% tõus

12 kuu keskmine prognoos

Keskmine 143.92 USD 49.37%

Kõrge 167 USD

Madal 125 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Rhythm Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Rhythm Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

60 / 65.58Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

126 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.